Could stem cell secretions help seniors regain muscle strength?

NCT ID NCT06600581

Ongoing Disease control Sponsor: Immunis, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a substance called IMM01-STEM, made from secretions of stem cells, can safely improve muscle performance in seniors aged 60-80 who have both obesity and muscle weakness (sarcopenic obesity). Participants receive injections twice a week for a period, and researchers monitor side effects and changes in walking speed and grip strength. The study involves 55 people and compares the treatment to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMM01-STEM (a mixture of molecules secreted by stem cells)
What this could lead to: If it works, this could lead to a new treatment that helps older adults with obesity and muscle weakness regain strength and mobility.
What could go wrong: This is a small, early-phase trial with only 55 participants. The treatment may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE PERFORMANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE PERFORMANCE SARCOPENIC OBESITY

Contacts and locations

Locations

Johnson Country Clinical Trials (JCCT)

Lenexa, Kansas, 66219, United States
National Institute of Clinical Research (NICR)

Garden Grove, California, 92844, United States
National Institute of Clinical Research (NICR)

Pomona, California, 91768, United States
Tekton Research

Wichita, Kansas, 67218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.